In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in connection with the public offering. All shares of

In addition, Savara has granted the underwriters a 30-day option to purchase up to 1,263,157 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Zambon SpA is purchasing 4,693,540 shares of our common stock in this offering Oct 25, 2017 (Marketwired via COMTEX) -- AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. SVRA, -3.80% an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. Savara Announces Pricing of Public Offering of Common Stock. AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. In addition, Savara has granted the underwriters a 30-day option to purchase up to 637,500 additional shares of its common stock at the public offering price, less the underwriting discounts and AUSTIN, Texas, June 7, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of an underwritten public offering of 9,034,210 shares of

26 Feb 2020 to offer and sell shares of its common stock in an underwritten public offering. Inc. Announces Proposed Public Offering of Common Stock.

Savara Announces Pricing of Public Offering of Common Stock. AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. In addition, Savara has granted the underwriters a 30-day option to purchase up to 637,500 additional shares of its common stock at the public offering price, less the underwriting discounts and AUSTIN, Texas, June 7, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of an underwritten public offering of 9,034,210 shares of In addition, Savara is offering to certain investors the right to purchase pre-funded warrants in lieu of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,

20 Feb 2020 Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( Nasdaq: BSGM) (“BioSig” or the “Company”), a medical 

20 Feb 2020 Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( Nasdaq: BSGM) (“BioSig” or the “Company”), a medical  3 Mar 2020 (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject  Moderna Announces Proposed Public Offering of Shares of Common Stock. February 10, 2020 at 4:13 PM EST. PDF Version. CAMBRIDGE, Mass. --( BUSINESS  HubSpot also intends to grant the underwriter a 30-day option to purchase up to an additional 255,000 shares of common stock. All of the shares in the proposed   26 Feb 2020 to offer and sell shares of its common stock in an underwritten public offering. Inc. Announces Proposed Public Offering of Common Stock. Jan-16-20 11:21AM, Is Savara Inc. (NASDAQ:SVRA) A Volatile Stock? Jul-25- 18 04:16PM, Savara Announces Proposed Public Offering of Common Stock 

Moderna Announces Proposed Public Offering of Shares of Common Stock. February 10, 2020 at 4:13 PM EST. PDF Version. CAMBRIDGE, Mass. --( BUSINESS 

Savara Announces Proposed Public Offering Of Common Stock /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to o SVRA, +1.74%, an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain investors the right to purchase pre-funded warrants in lieu of common stock. Savara Announces Pricing of Public Offering of Common Stock. AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. In addition, Savara has granted the underwriters a 30-day option to purchase up to 1,263,157 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Zambon SpA is purchasing 4,693,540 shares of our common stock in this offering

In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in connection with the public offering. All shares of

AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to o SVRA, +1.74%, an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain investors the right to purchase pre-funded warrants in lieu of common stock. Savara Announces Pricing of Public Offering of Common Stock. AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. In addition, Savara has granted the underwriters a 30-day option to purchase up to 1,263,157 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Zambon SpA is purchasing 4,693,540 shares of our common stock in this offering Oct 25, 2017 (Marketwired via COMTEX) -- AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. SVRA, -3.80% an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share.

Savara Announces Pricing of Public Offering of Common Stock. AUSTIN, TX--(Marketwired - October 25, 2017) - Savara, Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share.